drugset

drugset / Trial / NCT06696716

ONO-4059 Study in Patients With Steroid-resistant Pemphigus

NCT06696716 ↗

Phase 3 Active not recruiting 34 enrolled Ono Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus

Timeline

Start: 2022-08-15
Primary completion: 2027-09-30
Completion: 2029-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Tirabrutinib	Small molecule	80 mg	Oral

Indications